{
    "nctId": "NCT03979911",
    "briefTitle": "Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer",
    "officialTitle": "Evaluation of Double HER2 Blocking by Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, HER-2 Gene Amplification",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* metastatic breast cancer\n* HER2 positive\n* Received pertuzumab in combination with trastuzumab and taxane chemotherapy\n\nExclusion Criteria:\n\n* no HER2-positive breast cancer\n* no association with taxane chemotherapy\n* no metastatic breast cancer\n* refusal to consent",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}